SC Launch Company, KIYATEC Inc., Receives Grainger Grant
Funding to Support SC and University of Southern California Research
COLUMBIA, S.C. -- March 27, 2013
SCRA Technology Ventures’ SC Launch Program today announced that KIYATEC, Inc.
recently received a $30,000 Grainger Foundation Frontiers of Engineering
Grant. The grant was jointly awarded to KIYATEC CEO Matthew Gevaert and the
University of Southern California’s Andrea Armani to further the team’s work
to more accurately understand and predict human response to drugs.
KIYATEC, based in Greenville, SC, has received $575,000 in SC Launch
investments over the last four years. Using technologies developed and
licensed from Clemson University, the company has rapidly grown since its
inception in 2005, moving into Greenville Health System’s Institute for
Translational Oncology Research in 2011. KIYATEC’s location inside the
hospital gives the company a significant advantage in its mission to provide
meaningful data that links drug performance to patient outcomes. By doing so,
KIYATEC will benefit patients and save costs in both healthcare and drug
“This grant is the first step in a new, exciting collaboration,” said Gevaert.
“We are hopeful that the data we'll produce will lead to further funding for
this type of platform integration, an aspect of our quest to create ever
smarter, ever better cell culture systems.”
“The Grainger Grant is but one example of the national recognition KIYATEC is
receiving,” said SCRA CEO Bill Mahoney. “The SCRA Technology Ventures and SC
Launch teams congratulate Matt and KIYATEC on this achievement. Our SC Launch
companies continue to grow and produce quality technologies that are advancing
products and processes to improve lives. A second example of such national
recognition is KIYATEC’s upcoming podium presentation at the annual meeting of
the American Association for Cancer Research in Washington, DC on April 7th.
The company will present data on its ability to predict the effectiveness of
anti-cancer drugs before they are used in patients during clinical trials. We
look forward to KIYATEC’s future successes and partnerships.”
The Grainger Foundation, an independent, private foundation based in Lake
Forest, Illinois, was established in 1949 by William W. Grainger, founder of
W.W. Grainger, Inc. Grainger Grants provide seed funding for U.S- based
institutions to enable further pursuit of important new interdisciplinary
research and projects.
About SCRA and SCRA Technology Ventures
SCRA Technology Ventures helps innovative companies grow and develop new
technologies, creating jobs and advancing the Knowledge Economy throughout
South Carolina. This SCRA business sector provides support and mentoring
through its flagship SC Launch program to early stage, start-up technology
companies. Since 2006, SCRA has deployed over $59 million in funding and
infrastructure to support over 271 high -tech, early-stage enterprises, and
has directly invested over $13 million in South Carolina start-ups, attracting
over $212 million in private investment. SCRA Technology Ventures also
supports commercialization and growth by facilitating the transfer of
intellectual property and accelerating the transition of inventions to the
marketplace. Additionally, SCRA Technology Ventures invests in more
established technology companies through its Stage 2 affiliate.
Multiple economic impact studies show SCRA's cumulative output on South
Carolina's economy to be over $15.3 billion, and that the company has helped
create approximately 15,000 technology-related jobs in the state, with annual
wages averaging between $55,000 and $77,000.
KIYATEC provides advanced 3D cell-based assays for preclinical screening of
small molecules and biologics to assess toxicity and efficacy. As a contract
research service provider, we deploy physiologically relevant cell culture
techniques to more accurately predict anti-cancer efficacy, immune-related
hepatotoxicity, and cell response to implantable biomaterials.
KIYATEC offices and labs are located within the Institute for Translational
Oncology Research (ITOR) and co-located with the ITOR Clinical Research Unit
on the main campus of the Greenville Health System, the 13th largest public
hospital system in the US. We utilize primary sourced cells and tissues,
advanced proteomics, imaging and other analytical capabilities to provide
valuable data and insight to meet the needs of our pharmaceutical,
biotechnology and medical device company clients. Our qualified staff
specializes in complex 3D cell-based assays to deliver standardized and custom
in vitro models that better predict human response to drugs and devices.
Micki Howard MacNaughton, 843-760-3329
Press spacebar to pause and continue. Press esc to stop.